Russian Drug Market Sales Plunge 33% In 2 Years

11 September 1994

Drug sales on the Russian market are estimated to have declined by a third in the last two years, according to a report on the situation by the French consultancy group Eurosiris. This slump in sales is seen as further evidence of the implosion of the Russian economic and social system.

Between 1991 and 1993, drug sales to hospitals declined by only 11%, but pharmacy sales dropped 50%. The report says this is even more alarming than it appears, given that the state of health of the Russian population has also deteriorated in the last two years, with a multiplication of cases of diphtheria and a fresh rise in infant mortality.

Lower purchasing power is seen as one factor contributing to the present situation, but another factor singled out by the report is the collapse of the supply-side of the economy since the break-up of the USSR. Within the former system of division of labor in the COMECON economic group in eastern Europe, the production of drugs was assigned not to the USSR but to Hungary.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight